Discover our medicines
Our innovative medicines address society’s greatest disease burdens and restore possibility for patients.
Explore our science
Discover how we unravel the mysteries of biology and develop new technologies to fight disease and change lives.
Learn about our impact
Creating a medicine is just the beginning of the journey. Discover how we embrace societal impact as a core business objective.
Novartis Financial Results – Q1 2024
Novartis announced the company’s financial results for the first quarter of 2024.
Latest news
Novartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cash
Novartis highlights pioneering innovation in CML with data from Scemblix® Phase III ASC4FIRST study in newly diagnosed patients at ASCO and EHA
Novartis enters agreement to acquire Mariana Oncology, strengthening radioligand therapy pipeline
The burden of IgAN
IgAN nephropathy (IgAN) is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide. Novartis is working to slow the progression of this disease and extend a dialysis-free life in patients.
Novartis in Society Integrated Report 2023
Learn about our business, strategy and performance in 2023, and how we create sustainable value for stakeholders and society.